

1 **Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2**

2 **infection is associated with disease severity and fatal outcome**

3 Yang Yang†, Chenguang Shen†, Jinxiu Li†, Jing Yuan, Minghui Yang, Fuxiang Wang,  
4 Guobao Li, Yanjie Li, Li Xing, Ling Peng, Jinli Wei, Mengli Cao, Haixia Zheng,  
5 Weibo Wu, Rongrong Zou, Delin Li, Zhixiang Xu, Haiyan Wang, Mingxia Zhang,  
6 Zheng Zhang, Lei Liu\*, Yingxia Liu\*

7

8 Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research  
9 Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen  
10 Third People's Hospital, Second Hospital Affiliated to Southern University of Science  
11 and Technology, Shenzhen, China.

12

13 †These authors contributed equally.

14 \*email: yingxialiu@hotmail.com; liulei3322@aliyun.com

15

16 The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute  
17 respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, December  
18 2019, and continuously poses a serious threat to public health. Our previous study has  
19 shown that cytokine storm occurred during SARS-CoV-2 infection, while the detailed  
20 role of cytokines in the disease severity and progression remained unclear due to the  
21 limited case number. In this study, we examined 48 cytokines in the plasma samples  
22 from 53 COVID-19 cases, among whom 34 were severe cases, and the others

23 moderate. Results showed that 14 cytokines were significantly elevated upon  
24 admission in COVID-19 cases. Moreover, IP-10, MCP-3, and IL-1ra were  
25 significantly higher in severe cases, and highly associated with the PaO<sub>2</sub>/FaO<sub>2</sub> and  
26 Murray score. Furthermore, the three cytokines were independent predictors for the  
27 progression of COVID-19, and the combination of IP-10, MCP-3 and IL-1ra showed  
28 the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC)  
29 calculations. Serial detection of IP-10, MCP-3 and IL-1ra in 14 severe cases showed  
30 that the continuous high levels of these cytokines were associated with disease  
31 deterioration and fatal outcome. In conclusion, we report biomarkers that closely  
32 associated with disease severity and outcome of COVID-19. These findings add to  
33 our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection,  
34 providing novel therapeutic targets and strategy.

35

36 Coronaviruses are the largest known viruses with a single positive- sense genome of  
37 about 31Kb which could infect a wide range of different species, and mainly infect  
38 respiratory and intestinal tract causing a wide range of symptoms <sup>1</sup>. Six members of  
39 coronaviruses that have been found to infect human beings, including HCoV-229E,  
40 HCoVOC43, HCoV-NL63, and HCoV-HKU1, Severe Acute Respiratory Syndrome  
41 coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus  
42 (MERS-CoV) <sup>1,2</sup>. Until recently, human infection with the novel severe acute  
43 respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly identified in late  
44 December, 2019, in Wuhan, China <sup>3,4</sup>. As of Feb. 29, 2020, a total of 79824  
45 Coronavirus Disease 2019 (COVID-19) cases with 2870 fatal cases were reported <sup>5</sup>.  
46 Furthermore, another 53 countries have also reported COVID-19 cases, posing a  
47 serious threat of public health <sup>6</sup>. Studies have revealed that pneumonia is the most  
48 common complications following SARS-CoV-2 infection, and followed by acute  
49 respiratory distress syndrome (ARDS) <sup>7,8</sup>. Inflammation is the body's first coordinated  
50 line of defense against tissue damage caused by either injury or infection, involving  
51 activating both the innate and adaptive immune responses <sup>9</sup>. However, exuberant  
52 immune responses following infection have been described as a cytokine storm,  
53 associated with excessive levels of proinflammatory cytokines and widespread tissue  
54 damage including ARDS <sup>10</sup>.

55 Cytokine storm has been found during the infection of influenza viruses <sup>11-16</sup> as  
56 well as coronaviruses <sup>17-24</sup>, and contributes to acute lung injury and development of  
57 ARDS <sup>2</sup>. Preliminary studies have shown that SARS-CoV-2 infection triggers  
58 cytokine storm, and results in the increase of a variety of cytokine/chemokine <sup>25,26</sup>.  
59 However, the detailed role of cytokines in diseases severity and progression remains  
60 unknown. In this study, we recruited 53 COVID-19 cases with 34 severe cases and 19

61 moderate cases defined according to China National Health Commission Guidelines  
62 for Diagnosis and Treatment of SARS-CoV-2 infection, and analyzed the plasma  
63 cytokine/chemokine profile in detail. Most of the severe cases (73.5%) were  $\geq$  60  
64 years-old, while the moderate cases were mainly in the group of 16-59 years-old  
65 (63.2%) (Table S1). The initial symptoms, co-existing chronic medical conditions,  
66 intervals of illness onset to admission and antiviral treatment were similar between  
67 the two groups. Complications occurred more frequently in the severe cases,  
68 including ARDS, respiratory failure, hepatic and renal insufficiency (Table S1). A  
69 complete blood count with differential was assessed for each patient either on the date  
70 of hospital admission, or at the earliest time-point and thereafter (Table 1). The  
71 percentage of lymphocyte (LYM) and neutrophil (NEU) as well as the CD4 and CD8  
72 counts were significantly lower in the severe cases, indicating a possible dysfunction  
73 of immune responses.

74 Then the expression profile of cytokines/chemokines of COVID-19 cases upon  
75 admission was analyzed. Elevated concentrations of both pro- and anti-inflammatory  
76 cytokines were observed in these cases including IFN- $\gamma$  (interferon, IFN), IL-1ra  
77 (interleukin, IL), IL-2ra, IL-6, IL-10, IL-18, HGF (hepatocyte growth factor), MCP-3  
78 (monocyte chemotactic protein-3), MIG (monokine induced gamma interferon),  
79 M-CSF (macrophage colony stimulating factor), G-CSF (granulocyte  
80 colony-stimulating factor), MIG-1a (macrophage inflammatory protein 1 alpha)  
81 CTACK (cutaneous T-cell-attracting chemokine) and IP-10 (interferon gamma  
82 induced protein 10), when compared with healthy control, indicating that cytokine  
83 storm occurred following SARS-CoV-2 infection (Figure 1) as previously reported<sup>3,25</sup>.  
84 Similar phenomenon was also observed in SARS-CoV<sup>17-21</sup> and MERS-CoV<sup>22-24</sup>  
85 infected patients, despite that the expression profiles were virus specific. Meanwhile,

86 we compared the plasma cytokine/chemokine levels collected from severe and  
87 moderate cases at different days after illness onset (d.a.o). The results showed that  
88 most of the cytokines were comparable between the two groups and maintained high  
89 level even at the later stage of the disease ( $\geq 15$  d.a.o). However, IP-10, MCP-3,  
90 IL-1ra and MIG were significantly higher in samples from severe cases in all the three  
91 groups of sample collection time, even though statistical significance was not  
92 observed in IL-1ra and MIG. Notably, IP-10 in the severe cases possessed a high and  
93 similar expression level at all groups of sample collection time. On the contrary, IP-10  
94 in moderate cases was significantly lower and further decreased a lot at  $\geq 15$  d.a.o.  
95 Moreover, comparison of these fourteen cytokines between the severe and moderate  
96 cases showed significantly higher levels of IP-10, MCP-3 and IL-1ra in the severe  
97 cases (Figure 1). Spearman rank coefficient correlation analysis showed that IP-10,  
98 MCP-3 and IL-1ra expression levels were highly correlated with PaO<sub>2</sub>/FaO<sub>2</sub> and  
99 Murray scores. Interestingly, the viral load (displayed as Ct values) showed obvious  
100 correlation with only IP-10, while not MCP-3 and IL-1ra, as well as the PaO<sub>2</sub>/FaO<sub>2</sub>  
101 and Murray scores (Figure S2). Our previous study has found that the viral shedding  
102 in COVID-19 cases is complicated and the viral loads obtained from the regularly  
103 used upper respiratory specimens might not consistent with the real case, especially  
104 for the severe cases<sup>27</sup>. Meanwhile, the main distribution of viruses in the severe and  
105 moderate cases were also different, which might influence the induction of cytokines  
106 as well. Indeed, studies have found that high viral loads in some types of viral  
107 infections correlated with severe diseases<sup>28-30</sup>, while not for all of them<sup>31</sup>. These  
108 results suggested that the production of specific cytokines while not the viral burden  
109 might play central in the pathogenesis COVID-19.

110 We further analyzed whether these cytokines could be used as predictors for the

111 disease severity and progression of COVID-19. Firstly, we calculated the receiver  
112 operating characteristic (ROC) of each single cytokine using the expression levels  
113 upon admission. Results showed that the area under the curve (AUC) of the ROC was  
114 0.915, 0.765 and 0.792 for IP-10, MCP-3 and IL-1ra, respectively (Figure 3). Then  
115 we tested the different combination of these cytokines for the prediction of disease  
116 progression. Combinations of the three cytokines showed the highest AUC of 0.943,  
117 followed by the combination of IP-10 and MCP-3 (0.927) as well as the combination  
118 of IP-10 and IL-1ra (0.923) (Figure 3). Furthermore, we analyzed the serial change of  
119 the three cytokines in 14 severe cases. In the two fatal cases (cases 1 and 2), the  
120 expression levels were significantly high upon admission and maintained high levels  
121 during the disease progression. Meanwhile, five cases (cases 7~9, 11 and 13) with  
122 continuously high levels of these cytokines, especially IP-10 and MCP-3, were still in  
123 critical condition. On the contrary, cases 3~6, 10, 12 and 14 with lower levels or  
124 significantly decreased levels of these cytokines showed an obvious  
125 improvement of the disease, and became moderate cases (cases 4, 10, 12 and 14) or  
126 discharged from hospital (cases 3, 5, 6 and 10). These results indicated that these  
127 three cytokines could be considered as biomarkers to predict disease progression and  
128 outcome of SARS-CoV-2 infections.

129 Cytokine storm with uncontrolled proinflammatory responses induce significant  
130 immunopathology and severe disease outcomes during some viral infections,  
131 indicating an important role in the pathogenesis of these viruses <sup>2,32</sup>. Accordingly, not  
132 only the pathogens but also the pathogen induced cytokine storm should be  
133 considered during the treatment. Therapy strategy with a combination of antimicrobial  
134 and immunotherapy may produce a more favorable outcome <sup>9</sup>. Corticosteroids which  
135 could downregulate proinflammatory cytokine transcription and subsequently inhibit

136 the cytokine storm<sup>33</sup>, and the antiviral cytokine interferon- $\alpha$  were widely used during  
137 the treatment of COVID-19<sup>8,34</sup>. However, use of high-dose corticosteroids has been  
138 shown to be associated with an increase in mortality and significantly longer  
139 durations of viral shedding in H7N9 infected patients<sup>35</sup>, which is of concern. The  
140 results of our study suggested a crucial role of IP-10 in the pathogenesis of  
141 SARS-CoV-2, which has also been shown to be associated with disease severity of  
142 H5N1, H1N1, SARS-CoV and MERS-CoV<sup>16,24,29,36</sup>. A recent study has found that  
143 IP-10 (CXCL10)-CXCR3 signaling appears to be a critical factor for the exacerbation  
144 of the pathology of ARDS<sup>37</sup>. Thus, modulators such as antibody targeting IP-10  
145 might be a promising therapeutic strategy in the treatment of the acute phase of ARDS  
146 to ameliorates acute lung injury as shown in H1N1 mouse model<sup>37,38</sup>.

147 In summary, we compared the differences of cytokines profiles between severe and  
148 moderate COVID-19 cases, and found that IP-10, MCP-3 and IL-1ra were  
149 significantly associated with disease severity and progression of COVID-19. Our  
150 results added to our understanding of the immunopathologic mechanisms of  
151 SARS-CoV-2 infection, and suggest a novel therapeutic strategy using modulators or  
152 antibodies against theses cytokines, especially IP-10.

## 153 **METHODS**

### 154 **Patient information and data collection**

155 Subjects presented in this study were hospitalized COVID-19 patients (N=53), among  
156 whom 34 were defined as severe cases according to China National Health  
157 Commission Guidelines for Diagnosis and Treatment of 2019-nCoV infection.  
158 Healthy controls (N=8) were also included. Clinical information and laboratory result  
159 were collected at the earliest time-point after hospitalization. The study protocol was  
160 approved by the Ethics Committees of Shenzhen Third People's Hospital  
161 (SZTHEC2016001). Informed consents were obtained from all patients or patients  
162 family members. The study was conducted in accordance with the International  
163 Conference on Harmonisation Guidelines for Good Clinical Practice and the  
164 Declaration of Helsinki and institutional ethics guidelines.

### 165 **Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)**

166 qRT-PCR were done as previously reported<sup>26,34</sup>. In brief, throat swabs, nasal swabs,  
167 sputum and BALF specimens were collected from laboratory-confirmed COVID-19  
168 cases upon admission and thereafter. Viral RNAs were extracted from clinical  
169 specimens using the QIAamp RNA Viral Kit (Qiagen, Heiden, Germany). A China  
170 Food and Drug Administration (CDFA) approved commercially kit (GeneoDX Co.,  
171 Shanghai, China) were used for the detection of SARS-CoV-2 specific RNAs.  
172 Samples with a cycle threshold (Ct) value  $\leq 37.0$  were considered putatively positive.  
173 Samples whose Ct was higher than 37 were re-tested and considered positive if Ct  
174 was  $\geq 37$  but  $\leq 40$  and negative if viral RNAs were undetectable on the second test.

### 175 **Disease severity classification**

176 Disease severity classification and Murray Score calculation were evaluated as  
177 previously reported <sup>26</sup>. Severity of 2019-nCoV infection was graded according to  
178 China National Health Commission Guidelines for Diagnosis and Treatment of  
179 SARS-CoV-2 infection. Laboratory confirmed patients with fever, respiratory  
180 manifestations and radiological findings indicative of pneumonia were considered  
181 moderate cases (COVID-19-M). Laboratory confirmed patients who met any of the  
182 following were considered to have severe COVID-19 (COVID-19-S): 1) respiratory  
183 distraction (respiration rate $\geq$ 30/min; 2) resting oxygen saturation $\leq$ 93%, or 3) arterial  
184 oxygen partial pressure (PaO<sub>2</sub>) / fraction of inspired oxygen (FiO<sub>2</sub>)  $\leq$ 300 mmHg (1  
185 mmHg = 0.133 kPa). Laboratory confirmed patients who had any of the following  
186 were considered in critical condition: 1) respiratory failure requiring mechanical  
187 ventilation, 2) shock, or 3) failure of other organs requiring intensive care unit (ICU).

### 188 **Quantification of hypoxia and Murray Score**

189 The partial pressure of oxygen (PaO<sub>2</sub>) in arterial blood taken from the patients at  
190 various time-points after hospitalization is measured by the ABL90 blood gas  
191 analyzer (Radiometer). The fraction of inspired oxygen (FiO<sub>2</sub>) is calculated by the  
192 following formula:  $FiO_2 = (21 + \text{oxygen flow (in units of l/min)} \times 4) / 100$ . The  
193 PaO<sub>2</sub>/FiO<sub>2</sub> ratio (in units of mmHg) is calculated by dividing the PaO<sub>2</sub> value with the  
194 FiO<sub>2</sub> value. A PaO<sub>2</sub>/FiO<sub>2</sub> ratio less than or equal to 100 mmHg is considered one of  
195 the criteria for severe acute respiratory distress syndrome (ARDS). Murray Score  
196 were calculated as reported <sup>39</sup>.

### 197 **Cytokine and chemokine measurements**

198 The plasma of patients with laboratory-confirmed COVID-19 cases (N=53) were

199 collected at the earliest possible time-point after hospitalization and thereafter. The  
200 plasma of healthy subjects (N=8) were included as the negative control group. The  
201 concentrations of 48 cytokines and chemokines were measured using Bio-Plex Pro  
202 Human Cytokine Screening Panel (Bio-Rad) as previously reported<sup>15,26</sup>.

### 203 **Statistical analysis**

204 Fisher exact test was used to compare the indicated rates between the moderate and  
205 severe cases. Mann-Whitney U test was used to compare plasma cytokine levels  
206 between two groups. The Spearman rank correlation coefficient was used for linear  
207 correlation analysis between the expression level of plasma cytokine and PaO<sub>2</sub>/FiO<sub>2</sub>  
208 ratio, Murray score as well as viral loads of COVID-19 cases. The area under the  
209 receiver operating characteristic (ROC) curve (AUC) of plasma cytokine levels was  
210 estimated for the moderate and severe cases. All statistical tests were calculated using  
211 SPSS 20.0 for Windows (IBM, Chicago, USA). *P value* less than 0.05 was considered  
212 statistically significant.

213 **References**

- 214 1 Su, S. *et al.* Epidemiology, Genetic Recombination, and Pathogenesis of  
215 Coronaviruses. *Trends Microbiol* **24**, 490-502, doi:10.1016/j.tim.2016.03.003  
216 (2016).
- 217 2 Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections:  
218 causes and consequences of cytokine storm and immunopathology. *Semin*  
219 *Immunopathol* **39**, 529-539, doi:10.1007/s00281-017-0629-x (2017).
- 220 3 Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China,  
221 2019. *N Engl J Med*, doi:10.1056/NEJMoa2001017 (2020).
- 222 4 Wenjie, T. *et al.* A Novel Coronavirus Genome Identified in a Cluster of  
223 Pneumonia Cases — Wuhan, China 2019–2020. *China CDC Weekly* **2**, 61-62  
224 (2020).
- 225 5 China, N. H. C. o. t. P. s. R. o. *Daily briefing on novel coronavirus cases in*  
226 *China*, <[http://en.nhc.gov.cn/2020-02/05/c\\_76219.htm](http://en.nhc.gov.cn/2020-02/05/c_76219.htm)> (2020).
- 227 6 WHO. *Novel Coronavirus (COVID-19) situation*,  
228 <[https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125](https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd)  
229 [cd](https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd)> (2020).
- 230 7 Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients With  
231 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*,  
232 doi:10.1001/jama.2020.1585 (2020).
- 233 8 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in  
234 China. *N Engl J Med*, doi:10.1056/NEJMoa2002032 (2020).
- 235 9 D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A. & Clark, G. C.  
236 Targeting the "cytokine storm" for therapeutic benefit. *Clin Vaccine Immunol*  
237 **20**, 319-327, doi:10.1128/cvi.00636-12 (2013).
- 238 10 Ben Salem, C. Acute Respiratory Distress Syndrome. *N Engl J Med* **377**, 1904,  
239 doi:10.1056/NEJMc1711824 (2017).
- 240 11 Zeng, H. *et al.* A(H7N9) virus results in early induction of proinflammatory  
241 cytokine responses in both human lung epithelial and endothelial cells and  
242 shows increased human adaptation compared with avian H5N1 virus. *J Virol*  
243 **89**, 4655-4667, doi:10.1128/jvi.03095-14 (2015).

- 244 12 Guo, J. *et al.* The Serum Profile of Hypercytokinemia Factors Identified in  
245 H7N9-Infected Patients can Predict Fatal Outcomes. *Sci Rep* **5**, 10942,  
246 doi:10.1038/srep10942 (2015).
- 247 13 Zhou, J. *et al.* Biological features of novel avian influenza A (H7N9) virus.  
248 *Nature* **499**, 500-503, doi:10.1038/nature12379 (2013).
- 249 14 Yang, Y. *et al.* Comparison between human infections caused by highly and  
250 low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and  
251 virological findings. *J Infect* **78**, 241-248, doi:10.1016/j.jinf.2019.01.005  
252 (2019).
- 253 15 Bi, Y. *et al.* Clinical and immunological characteristics of human infections  
254 with H5N6 avian influenza virus. *Clin Infect Dis*, doi:10.1093/cid/ciy681  
255 (2018).
- 256 16 Wang, S. *et al.* Influenza virus-cytokine-protease cycle in the pathogenesis of  
257 vascular hyperpermeability in severe influenza. *J Infect Dis* **202**, 991-1001,  
258 doi:10.1086/656044 (2010).
- 259 17 Jiang, Y. *et al.* Characterization of cytokine/chemokine profiles of severe acute  
260 respiratory syndrome. *Am J Respir Crit Care Med* **171**, 850-857,  
261 doi:10.1164/rccm.200407-857OC (2005).
- 262 18 Huang, K. J. *et al.* An interferon-gamma-related cytokine storm in SARS  
263 patients. *J Med Virol* **75**, 185-194, doi:10.1002/jmv.20255 (2005).
- 264 19 Zhang, Y. *et al.* Analysis of serum cytokines in patients with severe acute  
265 respiratory syndrome. *Infect Immun* **72**, 4410-4415,  
266 doi:10.1128/iai.72.8.4410-4415.2004 (2004).
- 267 20 Wong, C. K. *et al.* Plasma inflammatory cytokines and chemokines in severe  
268 acute respiratory syndrome. *Clin Exp Immunol* **136**, 95-103,  
269 doi:10.1111/j.1365-2249.2004.02415.x (2004).
- 270 21 Dynamic changes in blood cytokine levels as clinical indicators in severe  
271 acute respiratory syndrome. *Chin Med J (Engl)* **116**, 1283-1287 (2003).
- 272 22 Mubarak, A., Alturaiki, W. & Hemida, M. G. Middle East Respiratory  
273 Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response,  
274 and Vaccine Development. *J Immunol Res* **2019**, 6491738,  
275 doi:10.1155/2019/6491738 (2019).

- 276 23 Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman,  
277 B. A. MERS-CoV infection in humans is associated with a pro-inflammatory  
278 Th1 and Th17 cytokine profile. *Cytokine* **104**, 8-13,  
279 doi:10.1016/j.cyto.2018.01.025 (2018).
- 280 24 Faure, E. *et al.* Distinct immune response in two MERS-CoV-infected patients:  
281 can we go from bench to bedside? *PLoS One* **9**, e88716,  
282 doi:10.1371/journal.pone.0088716 (2014).
- 283 25 Huang, C. *et al.* Clinical features of patients infected with 2019 novel  
284 coronavirus in Wuhan, China. *Lancet* **395**, 497-506,  
285 doi:10.1016/s0140-6736(20)30183-5 (2020).
- 286 26 Liu, Y. *et al.* 2019-novel coronavirus (2019-nCoV) infections trigger an  
287 exaggerated cytokine response aggravating lung injury. *ChinaXiv* (2020).
- 288 27 Yang, Y. *et al.* Laboratory diagnosis and monitoring the viral shedding of  
289 2019-nCoV infections. *medRxiv* (2020).
- 290 28 Ng, K. T. *et al.* Viral Load and Sequence Analysis Reveal the Symptom  
291 Severity, Diversity, and Transmission Clusters of Rhinovirus Infections. *Clin*  
292 *Infect Dis* **67**, 261-268, doi:10.1093/cid/ciy063 (2018).
- 293 29 de Jong, M. D. *et al.* Fatal outcome of human influenza A (H5N1) is  
294 associated with high viral load and hypercytokinemia. *Nat Med* **12**, 1203-1207,  
295 doi:10.1038/nm1477 (2006).
- 296 30 de La Vega, M. A. *et al.* Ebola viral load at diagnosis associates with patient  
297 outcome and outbreak evolution. *J Clin Invest* **125**, 4421-4428,  
298 doi:10.1172/jci83162 (2015).
- 299 31 Garcia-Maurino, C. *et al.* Viral Load Dynamics and Clinical Disease Severity  
300 in Infants With Respiratory Syncytial Virus Infection. *J Infect Dis* **219**,  
301 1207-1215, doi:10.1093/infdis/jiy655 (2019).
- 302 32 Guo, X. J. & Thomas, P. G. New fronts emerge in the influenza cytokine storm.  
303 *Semin Immunopathol* **39**, 541-550, doi:10.1007/s00281-017-0636-y (2017).
- 304 33 Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids--new  
305 mechanisms for old drugs. *N Engl J Med* **353**, 1711-1723,  
306 doi:10.1056/NEJMra050541 (2005).
- 307 34 Liu, Y. *et al.* Clinical and biochemical indexes from 2019-nCoV infected

308 patients linked to viral loads and lung injury. *Sci China Life Sci*,  
309 doi:10.1007/s11427-020-1643-8 (2020).

310 35 Cao, B. *et al.* Adjuvant Corticosteroid Treatment in Adults With Influenza A  
311 (H7N9) Viral Pneumonia. *Crit Care Med* **44**, e318-328,  
312 doi:10.1097/ccm.0000000000001616 (2016).

313 36 Peiris, J. S. *et al.* Re-emergence of fatal human influenza A subtype H5N1  
314 disease. *Lancet* **363**, 617-619, doi:10.1016/s0140-6736(04)15595-5 (2004).

315 37 Ichikawa, A. *et al.* CXCL10-CXCR3 enhances the development of  
316 neutrophil-mediated fulminant lung injury of viral and nonviral origin. *Am J*  
317 *Respir Crit Care Med* **187**, 65-77, doi:10.1164/rccm.201203-0508OC (2013).

318 38 Wang, W. *et al.* Monoclonal antibody against CXCL-10/IP-10 ameliorates  
319 influenza A (H1N1) virus induced acute lung injury. *Cell Res* **23**, 577-580,  
320 doi:10.1038/cr.2013.25 (2013).

321 39 Murray, J. F., Matthay, M. A., Luce, J. M. & Flick, M. R. An expanded  
322 definition of the adult respiratory distress syndrome. *Am Rev Respir Dis* **138**,  
323 720-723, doi:10.1164/ajrccm/138.3.720 (1988).

324

### 325 **Acknowledgement**

326 This work was supported by the National Natural Science Foundation of China (Grant  
327 81802004) and the National Science and Technology Major Project (Grants  
328 2018ZX10711001, 2017ZX10204401 and 2017ZX10103011), Shenzhen Science and  
329 Technology Research and Development Project (Grants JCYJ20180228162201541,  
330 202002073000001) Sanming Project of Medicine in Shenzhen (SZSM201412003,  
331 SZSM201512005).

### 332 **Author contributions**

333 Y. Liu, L. Liu, Z. Zhang and Y. Yang conceived and guided the project. Y. Yang, C.  
334 Shen, M. Yang carried out the experiments and analyzed the data. J. Li, J. Yuan, F.

335 Wang, Z. Wang, M. Cao, W. Wu, R. Zou, Y. Li, L. Xing, L. Peng, J. Wei, H. Zheng, Z.  
336 Xu, and H. Wang collected clinical samples and the data. Y. Yang wrote the  
337 manuscript. All the authors have read and approved the manuscript.

338 **Competing interests**

339 The authors declare no competing interests.

340 **Figure legends**

341 **Figure 1. Comparison of serum cytokine/chemokine concentrations between**  
342 **healthy volunteers and COVID-19 cases.** Samples from severe (N=34) and  
343 moderate (N=19) COVID-19 cases were collected at the earliest possible time-point  
344 after hospitalization for assays measuring the concentrations of 48 cytokines and  
345 chemokines, and healthy subjects (N=8) were involved as control. Values were  
346 graphed on a logarithmic scale and presented in units of pg/mL. *P values* between  
347 0.01-0.05, 0.001-0.01 and 0.0001-0.001 were considered statistically significant (\*),  
348 very significant (\*\*) and extremely significant (\*\*\*), respectively, whereas ns  
349 represents not significant.

350

351 **Figure 2. IP-10, MCP-3 and IL-1ra expression levels were highly correlated with**  
352 **PaO<sub>2</sub>/FiO<sub>2</sub> and Murray Score.** The expression levels of IP-10, MCP-3 and IL-1ra  
353 measured from plasma samples collected upon admission and thereafter and the  
354 corresponding PaO<sub>2</sub>/FiO<sub>2</sub> and Murray Score at the same day were analyzed using  
355 spearman rank correlation analysis. The *r values* and *p values* were shown.

356

357 **Figure 3. The ROC curve of plasma cytokine levels for patients with mild and**  
358 **severe SARS-CoV-2-infections.** The receiver operating characteristic (ROC) curve  
359 was calculated using SPSS. The area under the curve (AUC) of ROC for IP-10,  
360 MCP-3 and IL-1ra was estimated using the expression levels upon admission. The *P*  
361 values of all AUC for the three cytokines were less than 0.05.

362

363 **Figure 4. Dynamic changes of IP-10, MCP-10 and IL-1ra in 14 severe cases of**  
364 **COVID-19 with different outcome and progression.** The expression levels  
365 measured at the indicated time-points of 14 severe cases were shown. The fatal cases  
366 were marked in red. Cases in critical condition were marked in blue, and the others  
367 were cases with moderate disease or discharged at present.

368

369 **Figure S1. Comparison of the significantly elevated cytokines measured at**  
370 **different days post illness onset between severe and moderate COVID-19 cases.**  
371 The expression levels of 14 significantly elevated cytokines measured at different  
372 days post illness onset were shown and compared between the severe and moderate  
373 COVID-19 cases. *P values* between 0.01-0.05, 0.001-0.01 and 0.0001-0.001 were  
374 considered statistically significant (\*), very significant (\*\*) and extremely significant  
375 (\*\*\*), respectively, whereas ns represents not significant.

376

377 **Figure S2. Correlations between viral load and the cytokines of IP-10, MCP-3**  
378 **and IL-1ra, as well as PaO<sub>2</sub>/FiO<sub>2</sub> and Murray Score.** The correlations between  
379 viral load and the cytokines of IP-10, MCP-3 and IL-1ra, as well as PaO<sub>2</sub>/FiO<sub>2</sub> and  
380 Murray Score were analyzed using spearman rank correlation analysis. The *r values*  
381 and *p values* were shown. The viral loads were indicated as Ct values, and lower Ct  
382 values represented high viral load.






Figure 2




Figure 3




Figure 4




Figure S1




Figure S2

**Table 1. Laboratory results of COVID-19 patients in this study.**

Variables†	Total (N=53)	Severe (N=34)	Moderate (N=19)	P values
WBC ( $\times 10^9/L$ )	4.52 (3.43-5.89)	4.745 (3.54-5.91)	4.02 (3.42-5.55)	0.5623
LYM (%)	21.6 (15.1-32.1)	20.65(13.13-25.33)	29.40 (19.45-35.05)	0.0288
LYM ( $\times 10^9/L$ )	1.12 (0.89-1.48)	1.13 (0.92-1.44)	1.12 (0.89-1.51)	0.7873
NEU (%)	67.4 (57.0-77.4)	69.95 (61.35-79.93)	60.90 (52.95-69.30)	0.0358
NEU ( $\times 10^9/L$ )	2.8 (1.81-3.77)	2.98 (2.12-3.7)	2.32 (1.75-4.28)	0.5832
PLT ( $\times 10^9/L$ )	171 (138-199)	173(141.5-192)	151 (133-204)	0.6172
AST (U/L)	33 (24-43)	32(22.5-41.5)	33 (24.5-45)	0.8358
ALT (U/L)	26 (16-30)	24.5 (18-29.25)	26 (15-33)	0.5656
TB (umol/L )	9.5 (7.8-12.1)	9.4 (8.10-11.6)	10.3 (6.85-15.35)	0.2973
CRE ( $\mu\text{mol/L}$ )	72.7 (54-82)	71.85 (54-80.75)	76 (59-96.5)	0.7739
BUN (mmol/L)	6.68 (3.65-5.59)	5.05 (3.71-5.84)	4.32 (3.57-5.17)	0.0829
CK (U/L)	100 (55.5-126)	83.5(56-126)	100 (55.75-122.5)	0.8519
CK-MB (ng/mL)	0.76 (0.28-1.21)	0.73 (0.28-1.02)	0.89 (0.375-1.775)	0.9289
LDH (U/L)	411.5 (205-530.75)	337(184-525)	432 (223-532)	0.5117
CRP (mg/L)	14.05 (5.7-29.96)	13.33 (5.1-28.28)	15.2 (11.37-32.46)	0.2033
PCT (ng/mL)	0.05 (0.031-0.077)	0.54(0.04-0.08)	0.041 (0.030-0.090)	0.5672
CD4 (count/ $\mu\text{l}$ )	362 (217.5-547.25)	329 (200.25-438.5)	559.5(377-784)	0.0027
CD8 (count/ $\mu\text{l}$ )	159 (122.5-335)	139 (97-183)	453.5 (232.8-586)	0.0167
CD4/CD8	2.05 (1.3-2.48)	2.26(1.35-2.82)	1.71 (1.21-2.17)	0.1391

† Values shown represent the mean and inter-quartile range (IQR).

**Table S1. Epidemiological and clinical features of COVID-19 patients in this study.**

Characteristics	Total	Severe	Moderate	P values
-----------------	-------	--------	----------	----------

	(N=53)	(N=34)	(N=19)	
<b>Median age (range)</b>	62 (51-65)	63.5(42-74)	51 (22-78)	0.0012
<b>Age subgroups</b>				
0-15 years	0/53 (0%)	0/26(0%)	0/27 (0%)	1
16-59 years	21/53 (39.6%)	9/34(26.5%)	12/19 (63.2%)	0.0179
≥60 years	32/53 (60.4%)	25/ 34(73.5%)	7/19 (36.8%)	0.0179
<b>Male (%)</b>	31/53 (58.5%)	22/ 34(64.7%)	9/19 (47.3%)	0.2557
<b>Initial symptoms</b>				
Fever	44/53 (83.0%)	31/34 (91.2%)	13/19 (68.4%)	0.0555
Cough	36/53 (67.9%)	24/34 (70.6%)	12/19 (63.2%)	0.7597
Headache	6/53 (11.3%)	5/34 (14.7%)	1/19( 5.3%)	0.4020
Myalgia	28/53 (52.8%)	22/34 (57.7%)	6/19 (48.1%)	0.0254
Chill	6/53 (11.3%)	6/34 (17.6%)	0/19 (0%)	0.0770
Nausea or vomiting	0/53 (0%)	0/34 (0%)	0/19 (0%)	1
Diarrhea	4/53 (7.5%)	4/34 (11.8%)	0/19(0%)	0.2841
<b>Co-existing chronic medical conditions</b>				
Chronic heart disease	19/31 (82.6%)	16/24 (65.0%)	3/7 (50%)	0.3839
Chronic lung disease	2/31 (8.7%)	1/24 (4.6%)	1/7 (14.3%)	0.4065
Chronic renal disease	2/31 (6.5%)	2/24 (8.3%)	0/7 (0%)	0.5402
Chronic liver disease	2/31 (8.7%)	1/24 (4.6%)	1/7 (14.3%)	1
Diabetes	6/31 (19.4%)	4/24 (16.7%)	2/7 (28.6%)	0.5959
Cancer	4/31 (12.9%)	2/24 (8.3%)	1/7 (14.3%)	0.5497
<b>Bacterial co-infections</b>	11/53 ( 20.8% )	8/34(23.5%)	3/19(15.8%)	0.7264
<b>Interval, median days (IQR)<sup>+</sup></b>				
Onset to admission	4 (2, 6)	4 (3, 7)	2 (2, 5)	0.2287
Onset to starting antiviral treatment	4 (3, 7)	4 (4, 7)	4 (2.5, 6.5)	0.9184
<b>Complications</b>				
Pneumonia	53/53 (100%)	34/34 (100%)	19/19 (100%)	1
ARDS	37/53 (71.6%)	33/34 (97.1%)	0/19 (0%)	<0.0001
Hepatic insufficiency	14/53 (26.4%)	13/34 (38.2%)	1/19 (5.3%)	0.0099
Renal insufficiency	10/53 (18.9%)	10/34 (29.4%)	0/19 (0%)	0.0091
Cardiac failure	3/53 (5.7%)	3/34 (8.8%)	0/27 (0%)	0.5450
Shock	2/53 (3.8%)	2/34 (5.8%)	0/27 (0%)	0.5312
<b>Treatment</b>				
Received antivirals ≤ 2 days after illness onset	9/53 ( 16.9% )	4/34(11.8%)	5/19(26.3%)	0.2550
Received antivirals 3-5 days after illness onset	23/53 ( 43.4% )	14/34(41.2%)	9/19(47.3%)	0.7750
Received antivirals ≥ 6 days after illness onset	21/53 ( 39.6% )	14/34(42.2%)	7/19(36.8%)	0.7794

---

Corticosteroid	16/53 ( 30.2% )	13/34(38.2%)	3/19(15.8%)	0.1226
Mechanical ventilation	25/53 (47.2%)	23/34 (67.7%)	0/19 (0%)	<0.0001
Invasive mechanical ventilation	9/53 (17.0%)	9/34 (26.5%)	0/19 (0%)	0.0188

---